Changes to the Code
S. 3794 · SAFE Drugs Act of 2026 · Reported The text a committee sent back to its chamber, often with changes, recommending a vote.
Reported by committee · step 2 of 5
21 U.S.C. § 353a Pharmacy compounding
5 changes the bill asks for here, 5 carried out
- Carried out:
by redesignating subsections (d) and (e) as subsections (e) and (f), respectively; and
- Carried out:
by inserting after subsection (c) the following:
(d) Reporting.— (1) Serious adverse events.— Each licensed pharmacist or licensed physician who compounds drug products under this section and sends such drug products, or causes such drug products to be sent, out of the State in which the compounding occurs shall submit any …
- Carried out:
in subparagraph (A), by striking
; and
and inserting a semicolon;
- Carried out:
in subparagraph (B)(ii), by striking the period and inserting
; and
; and - Carried out:
by inserting after subparagraph (B) the following:
(C) the label of such drug product includes— (i) the statement: “This medication has been compounded for dispensing to an individual patients and has not been approved by the Food and Drug Administration.”; (ii) the following information to facilitate adverse event reporting: …
§ 353a(b)–(f)
Start of § 353a to (b)(2) unchanged ·
(3) Drug product A drug product may be compounded under subsection (a) only if—
(A) such drug product is not a drug product identified by the Secretary by regulation as a drug product that presents demonstrable difficulties for compounding that reasonably demonstrate an adverse effect on the safety or effectiveness of that drug product;[struck: and]
(B) such drug product is compounded in a State—
(i) that has entered into a memorandum of understanding with the Secretary which addresses the distribution of inordinate amounts of compounded drug products interstate and provides for appropriate investigation by a State agency of complaints relating to compounded drug products distributed outside such State; or
(ii) that has not entered into the memorandum of understanding described in clause (i) and the licensed pharmacist, licensed pharmacy, or licensed physician distributes (or causes to be distributed) compounded drug products out of the State in which they are compounded in quantities that do not exceed 5 percent of the total prescription orders dispensed or distributed by such pharmacy or physician[struck: .][inserted: ; and]
(C) [inserted: the label of such drug product includes—]
(i) [inserted: the statement: “This medication has been compounded for dispensing to an individual patients and has not been approved by the Food and Drug Administration.”;]
(ii) [inserted: the following information to facilitate adverse event reporting: www.fda.gov/medwatch, and 1–800–FDA–1088 (or any successor website or telephone number); and]
(iii) [inserted: such other information as the Secretary may prescribe by order, which may include information to facilitate adverse event reporting.]
The Secretary shall, in consultation with the National Association of Boards of Pharmacy, develop a standard memorandum of understanding for use by the States in complying with subparagraph (B)(i).
(c) Regulations
(1) In general The Secretary shall issue regulations to implement this section. Before issuing regulations to implement subsections (b)(1)(A)(i)(III), (b)(1)(C), or (b)(3)(A), the Secretary shall convene and consult an advisory committee on compounding unless the Secretary determines that the issuance of such regulations before consultation is necessary to protect the public health. The advisory committee shall include representatives from the National Association of Boards of Pharmacy, the United States Pharmacopoeia, pharmacy, physician, and consumer organizations, and other experts selected by the Secretary.
(2) Limiting compounding The Secretary, in consultation with the United States Pharmacopoeia Convention, Incorporated, shall promulgate regulations identifying drug substances that may be used in compounding under subsection (b)(1)(A)(i)(III) for which a monograph does not exist or which are not components of drug products approved by the Secretary. The Secretary shall include in the regulation the criteria for such substances, which shall include historical use, reports in peer reviewed medical literature, or other criteria the Secretary may identify.
(d) [inserted: Reporting.—]
(1) [inserted: Serious adverse events.—] [inserted: Each licensed pharmacist or licensed physician who compounds drug products under this section and sends such drug products, or causes such drug products to be sent, out of the State in which the compounding occurs shall submit any report received by such licensed pharmacist or licensed physician of a serious adverse event associated with a compounded drug product, in accordance with the content and format requirements established through guidance or under section 310.305 of title 21, Code of Federal Regulations (or any successor regulations), to—]
(A) [inserted: the Secretary;]
(B) [inserted: the State in which the compounding occurs; and]
(C) [inserted: each State to which such drugs are sent.]
(2) [inserted: Interstate dispensing.—]
(A) [inserted: In general.—] [inserted: Beginning with the first calendar year that begins after the date of enactment of the SAFE Drugs Act of 2026, not later than January 15 of each calendar year, each licensed pharmacist or licensed physician who compounds drug products under this section and sends, or causes to be sent, out of the State in which the compounding occurs, more than 5 percent of the total annual amount of drug products compounded by such licensed pharmacist or licensed physician shall annually submit a report containing the information described in subparagraph (B) to the Secretary and the State to which such drug products are sent.]
(B) [inserted: Contents.—] [inserted: Each report under subparagraph (A) shall identify—]
(i) [inserted: the name, address, license number, and State of license of the licensed pharmacist or licensed physician who compounded the drug product; and]
(ii) [inserted: the total number of units of compounded drug products, by type of product, and by month, sent or caused to be sent to each applicable State.]
(C) [inserted: Form and manner.—] [inserted: A licensed pharmacist or licensed physician shall submit each report under subparagraph (A) in such form and manner as the Secretary may prescribe.]
(D) [inserted: Information sharing.—] [inserted: The Secretary shall use an information sharing system for purposes of facilitating the transmission of reports under subparagraph (A) from a licensed pharmacist or licensed physician to the Secretary and each applicable State in a manner that reduces unnecessary administrative burden.]
(E) [inserted: Exclusion.—] [inserted: This subsection shall not apply to the compounding of any drug products for hospital patients by a pharmacy located on the premises of the hospital.]
(3) [inserted: Rule of construction.—] [inserted: Nothing in this section shall be construed to preempt any requirement of a State or political subdivision of a State that requires additional, more stringent, or supplementary reporting with respect to a drug product compounded under this section.]
[struck: (d)] [inserted: (e)] Application This section shall not apply to—
(1) compounded positron emission tomography drugs as defined in section 321(ii) of this title; or
(2) radiopharmaceuticals.
[struck: (e)] [inserted: (f)] “Compounding” defined As used in this section, the term “compounding” does not include mixing, reconstituting, or other such acts that are performed in accordance with directions contained in approved labeling provided by the product’s manufacturer and other manufacturer directions consistent with that labeling.